{"DataElement":{"publicId":"2741610","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Preparative Regimen Other Type Therapies Specify","preferredDefinition":"The free-text field to describe another radiolabeled monoclonal antibody preparative regimen.","longName":"RAB_PRP_RG_OTR_TP_SP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2741608","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Preparative Regimen Other Type","preferredDefinition":"Any compound that has been joined with a radioactive substance._An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment._The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._Different than the one(s) previously specified or mentioned._Something distinguishable as an identifiable class based on common qualities.","longName":"RAB_PRP_RG_OTR_TP","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2741519","version":"1","preferredName":"Radiolabeled Monoclonal Antibody Preparative Regimen","preferredDefinition":"Any compound that has been joined with a radioactive substance.:An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C18138:C20401:C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiolabeled","conceptCode":"C18138","definition":"Any compound that has been joined with a radioactive substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-459B-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"ONEDATA","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2236666","version":"1","preferredName":"Other Type","preferredDefinition":"Different than the one(s) previously specified or mentioned. (NCI):A subdivision of a particular kind of thing.","longName":"C17649:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC571F-6DA8-4435-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AED73C4-DB9D-6E28-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018810","version":"1","preferredName":"Therapies Specify","preferredDefinition":"the free text field related to therapy.","longName":"TX_SPEC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184338","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"Specify","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2084-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BA236E-6B3E-350B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-03-25","modifiedBy":"CAMPBELB","dateModified":"2008-03-28","changeDescription":"released as entered during ISO compliance update","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2842912","version":"1","longName":"Therapy","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2842913","version":"1","longName":"Best Response","context":"NHLBI"},{"publicId":"2842917","version":"1","longName":"Supportive","context":"NHLBI"},{"publicId":"2865266","version":"1","longName":"Drug","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_prep_oth_rmab_spe","type":"NMDP_FN","context":"NHLBI"},{"name":"MaterialName:nameCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the other type of the","type":"Preferred Question Text","description":"Specify the other type of the radiolabeled monoclonal antibody preparative regimen:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2741610","type":"BRIDG Mapping Path","description":"PerformedProcedure > DefinedProcedure > Biologic > MaterialName.nameCode WHERE Biologic.typeCode = \"Radiolabeled Monoclonal Antibody\" AND DefinedProcedure > DefinedCompositeRelationship > DefinedActivity AND DefinedActivity.nameCode = \"Perform composite preparative regimen\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AED73C4-DBB9-6E28-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"KUMMEROA","dateModified":"2021-04-30","changeDescription":". .1/9/14mn-added Bridg info. 2021-4-30 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}